Brief: Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting On Neurofilament Biomarker Analysis Plan And Confirms Two Additional FDA Meetings
30/06/2025 13:17
Clene Inc. CLNN.O: CLENE PROVIDES REGULATORY UPDATE FOLLOWING CONSTRUCTIVE FDA TYPE-C MEETING ON NEUROFILAMENT BIOMARKER ANALYSIS PLAN AND CONFIRMS TWO ADDITIONAL FDA MEETINGS CLENE INC. - CONFIRMS TWO ADDITIONAL FDA MEETINGS FOR Q3 2025 CLENE INC. - ON TRACK FOR ALS NDA SUBMISSION IN Q4 2025 CLENE INC. - NFL EAP BIOMARKER ANALYSES TO BE CONDUCTED EARLY Q4 2025 CLENE INC. - FDA PROVIDES SUPPORTIVE FEEDBACK ON CLENE'S BIOMARKER ANALYSIS PLAN Source text: ID:nGNX45gB20 Further company coverage: CLNN.O
Recent news on Clene
See all newsClene Inc reports results for the quarter ended June 30 - Earnings Summary
Clene Q2 net loss widens on higher other expenses
Clene Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Clene Inc - Enters Second Amendment To Senior Secured Convertible Notes - SEC Filing
Clene Q1 loss widens on warrant liability issuance costs